The present disclosure relates to an isolated anti-AAV (adeno-associated virus) antibody or an antigen-binding fragment thereof capable of specifically binding an epitope of AAVrh74 capsid protein and uses thereof.

The invention relates to modified HPV particles that can be used therapeutically. Modified HPV particles may be used to deliver therapeutic agents, including siRNA molecules. Modified HPV particles may be used for the treatment of diseases or conditions of mucosal tissue, including HPV (human papilloma virus) infection and HPV-related tumors.

Provided are various embodiments relating to parvovirus antibodies, including caninized, felinized, and chimeric antibodies, that bind to canine and/or feline parvovirus, for example, having improved expression characteristics. In various embodiments, the parvovirus antibodies have ADCC, ADCP, and/or CDC effector functions. In various embodiments, such monoclonal parvovirus antibodies can be used in methods to prevent and/or treat parvoviral infection in subjects, such as dogs and cats. For example, the parvovirus antibodies provided may be used to provide passive immunity against infection with a canine or feline parvovirus.

Antibodies and compositions of matter useful for the detection, diagnosis and treatment of Epstein Barr Virus infection in mammals, and to methods of using those compositions of matter for the same. Also disclosed are proteins, referred to as anti-gp350 antibody probes, and anti-gp350 B-cell probes, that maintain the epitope structure of the CR2-binding region of gp350, but do not bind CR2.

The present invention provides monoclonal antibodies that bind to the Middle East Respiratory Syndrome-Coronavirus (MERS-CoV) spike protein, and methods of use. In various embodiments of the invention, the antibodies are fully human antibodies that bind to MERS-CoV spike protein. In some embodiments, the antibodies of the invention are useful for inhibiting or neutralizing MERS-CoV activity, thus providing a means of treating or preventing MERS infection in humans. In some embodiments, the invention provides for a combination of one or more antibodies that bind to the MERS-CoV spike protein for use in treating MERS infection. In certain embodiments, the one or more antibodies bind to distinct non-competing epitopes comprised in the receptor binding domain of the MERS-CoV spike protein.

The invention relates to a novel porcine circovirus type 2 (PCV2) strain. The invention also relates to immunogenic compositions containing the novel PCV2 strain, PCV2 test kits, and applications of the novel PCV2 strain.

Provided are novel human-derived antibodies specifically recognizing polyomavirus polypeptides, preferably capable of binding to polyomaviruses of the type of JC virus (JCV) and/or BK virus (BKV) as well as methods related thereto. Furthermore, assays and kits related to antibodies specific for polyomaviruses, polyomavirus VP1 and or polyomavirus VP1 Virus-Like Particles (VLPs), preferably of the type of JCV and/or BKV, are disclosed. The human-derived antibodies as well as binding fragments, derivatives and variants thereof can be used in pharmaceutical and diagnostic compositions for polyomavirus targeted immunotherapy and diagnostics.

A phage specific antibody presenting particle, devices and methods related to detection of phage amplification are provided. Specifically, described herein are compositions and methods for detecting Listeria bacteria using an antibody that recognized A511 anti-Listeria phage, wherein the antibody is conjugated to a nanoparticle that can be detected by surface-enhanced Raman scattering (SERS).

Synbodies specific for Norovirus and coupled with a substrate provide Norovirus binding and detection platforms (FIG. 1). A Norovirus capturing platform, comprising one or more synbodies selected from the group consisting of synbodies 6-6, 92-92, 93-93, and 94-94 coupled to a substrate, has been found to found to bind with either GII.4 Minerva or both GII.4 Minerva and GII.4 Sydney# strains of norovirus.

Synbodies specific for Norovirus and coupled with a substrate provide Norovirus binding and detection platforms (FIG. 1). A Norovirus capturing platform, comprising one or more synbodies selected from the group consisting of synbodies 6-6, 92-92, 93-93, and 94-94 coupled to a substrate, has been found to found to bind with either GII.4 Minerva or both GII.4 Minerva and GII.4 Sydney# strains of norovirus.